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Summary The in vitro activity of the novel chloroethylating agent, Clomesone, was investigated in a panel of
established murine and human tumour cell lines. In vivo anti-tumour activity was examined against three
transplantable adenocarcinomas of the mouse colon and in vivo bone marrow toxicity was assessed using a
spleen colony forming unit assay. The pharmacokinetic behaviour of the drug in vivo and drug stability in vitro
was analysed by gas chromatography with electron capture detection. Clomesone exhibited no activity in vitro
against the majority of cell lines derived from solid human colorectal carcinomas. Anti-tumour activity against
the murine tumours in vivo was not impressive and was accompanied by myelosuppression. Pharmacokinetic
data suggested that the lack of in vivo activity was due to the failure to achieve effective anti-neoplastic drug
concentrations at the tumour site. It was concluded that this study found no evidence to suggest that
Clomesone was toxicologically more selective than the chloroethylnitrosoureas.
Clinical responses to cytotoxic agents have been largely
restricted to the haematological malignancies while the
majority of human solid tumours have remained refractory
to chemotherapy (Marsoni et al., 1987). Thus the search for
more effective compounds has continued. Chloroethylnit-
rosoureas are highly active anti-neoplastic agents with a
broad spectrum of anti-tumour activity in experimental
systems. However, their clinical usefulness has been limited
by non-selective host toxicity, particularly myelosuppres-
sion.
The chloroethylnitrosoureas decompose spontaneously in
aqueous solution to generate reactive intermediates that are
capable of alkylating and carbamoylating nucleophilic targets
(Cheng et al., 1972). Alkylation reactions consist of
chloroethylations and hydroxyethylations of DNA (Tong et
al., 1982). Chloroethylation of 06-guanine with subsequent
cross-link formation is considered to be the most important
cytotoxic reaction (Lown et al., 1978) while hydroxyethyla-
tion reactions are thought to be responsible for their
mutagenic and carcinogenic effects (Pelfrene et al., 1976;
Swenson et al., 1979). Carbamoylating activity is not
required for cytotoxicity but does contribute to the overall
effect, probably by inhibiting DNA repair (Erickson et al.,
1980) and it has been suggested that the carbamoylating
activity of some chloroethylnitrosoureas could interfere with
the ability of normal cells to recover from the action of these
drugs (Sariban et al., 1984).
In the search for other types of compound that would
chloroethylate DNA, a series of 2-haloethylsulphonates was
synthesised (Shealy et al., 1983). 2-Chloroethyl(methyl-
sulphonyl)methanesulphonate (Clomesone), the most active
analogue tested, was shown to be highly effective against
P388 leukaemia in vivo (Shealy et al., 1984). The chemical
structure of Clomesone is shown in Figure 1. Clomesone was
further evaluated against a spectrum of animal tumour
models and was found to be generally as effective as the
chloroethylnitrosoureas (Dykes et al., 1989).
The results of an investigation of the action of Clomesone
in vitro indicated that it affected cellular DNA in a manner
similar to the chloroethylnitrosoureas with cross-link forma-
tion via chloroethylation of 06-guanine residues (Gibson et
al., 1985). However, it was found to be more specific in its
reaction with DNA in that it produced less variety of prod-
ucts than the chloroethylnitrosoureas with no apparent
generation of hydroxyethyl adducts (Gibson et al., 1986). In
addition, the chemical nature of Clomesone precludes the
formation of isocyanate breakdown products (Shealy et al.,
1984). It was suggested that this lack of carbamoylating
potential of Clomesone, together with the lack of hydroxy-
ethylating activity, might result in fewer unwanted side reac-
tions and that Clomesone would be a more toxicologically
selective agent. On this basis Clomesone was selected for
clinical development and is presently undergoing Phase 1
clinical trials in the UK.
Recently, the NCI has introduced a new disease-orientated
screening programme based on the assessment of the in vitro
cytotoxicity of a panel of cell lines representing the common
clinical forms of human cancers using a colorimetric assay
(Boyd, 1989). While in vitro colorimetric assays have the
advantage that they can rapidly evaluate novel anti-tumour
agents against a large number of cell lines, a recent review of
the literature has revealed that marked differences in the
response of cells in vitro and tumours in vivo exist (Phillips et
al., 1990). One reason for this discrepancy is that the in vitro
tests ignore the potential role played by the pharmacokinetic
behaviour and bioavailability of a drug in determining
tumour responses in vivo. This has led some workers to
advocate that appropriate transplantable mouse tumour
models, similar in sensitivity to solid cancers in man where
therapeutic indices are low, also have a role in the pre-clinical
evaluation of novel compounds which should include toxi-
cological and pharmacokinetic studies (Corbett et al., 1987;
Double & Bibby, 1989).
A series of transplantable murine adenocarcinomas of the
colon (MAC tumours) has been shown to exhibit a similar
spectrum of histology and chemosensitivity to human large
bowel cancer with responses to standard agents only nor-
mally seen close to the maximum tolerated dose (Double &
Ball, 1975). It has been used extensively as part of the
pre-clinical evaluation of new anti-cancer agents within the
Screening and Pharmacology Group of the EORTC (Bibby
et al., 1988b).
The feasibility of performing minimal toxicity studies in
conjunction with anti-tumour studies has been described
(Bibby et al., 1988b). Measurement of bone marrow damage,
the major dose-limiting toxicity of the chloroethylnitro-
soureas, will aid the identification of alternative chloro-
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Figure 1 Structure of Clomesone.
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ethylating agents with improved therapeutic indices. The
assessment of stem cell survival has been recommended to
study irreversible cytotoxic bone marrow injury (Schofield,
1986) and this can be performed readily in mice using a
spleen colony forming unit assay.
The purpose of this present study was to further evaluate
the novel chloroethylating agent, Clomesone. In vitro activity
was assessed against a panel of established murine and
human tumour cell lines while in vivo anti-tumour responses
were evaluated against an ascitic tumour, MAC 15A, and
two solid subcutaneous (sc) tumours, MAC 13 and MAC 26.
MAC 13 is relatively nitrosourea-sensitive due to a low level
of the repair enzyme 06-alkylguanine-DNA alkyltransferase
while MAC 26 is relatively nitrosourea-resistant due to a
high repair enzyme level (Lunn et al., 1989). In vivo bone
marrow toxicity and pharmacokinetic studies and in vitro
drug stability studies were performed in conjunction with the
anti-tumour studies. A novel, clinically active nitrosourea,
1-(2-chloroethyl)-3-[2-(dimethylaminosulphonyl)ethyl]-I-nitro-
sourea (TCNU) and a non-carbamoylating nitrosourea,
Chlorozotocin, were included in the study as reference com-
pounds.
Materials and methods
Test compounds
Clinically formulated Clomesone was obtained from Dr S.M.
Crawford through his involvement in the ongoing Phase I
clinical trial. Chlorozotocin was received from the NCI while
TCNU was a gift from Pharmacia Leo Therapeutics, Hels-
ingborg, Sweden. Clomesone was dissolved in sterile water
while TCNU was dissolved in 0.9% sterile saline.
Chlorozotocin was dissolved in 10% dimethylsulphoxide
(DMSO)/arachis oil. Drug solutions were prepared at an
appropriate concentration for the desired in vivo dose to be
administered in 0.1 ml per 10g body weight by intra-
peritoneal (ip) or intravenous (iv) injection and for the
desired final concentration in vitro to be achieved upon a 1 in
10 dilution.
In vitro studies
Cell culture The in vitro activity of Clomesone was assessed
against a panel ofestablished tumour cell lines (Phillips et al.,
1992) which consisted of three murine colon adenocar-
cinomas (MAC 1SA, MAC 16, MAC 26), a murine
myelomonocytic leukaemia (WEHI-3B), a human chronic
myelogenous leukaemia (K562), a human rectal carcinoma
(HRT-18) and four human colon adenocarcinomas (DLD-1,
HT-29, HCT-18, HCLO). They were routinely maintained as
monolayer cultures, except K562, WEHI-3B and MAC 16
which do not adhere strongly to plastic cultures vessels, in
RPMI 1640 tissue culture medium containing sodium
pyruvate (1 mM), penicillin/streptomycin (50 IUml I/
50pgml-') and supplemented with 10% foetal calf serum.
Chemosensitivity testing In vitro chemosensitivity was assessed
using a modified micro-tetrazolium (MTT) assay (Twenty-
man & Luscombe, 1987). Cell suspensions were obtained
from monolayer cultures in the exponential growth phase
and 0.5-1.0 x 104 tumour cells in culture medium were
plated into 96-well dishes. Drug solutions were added to give
final concentrations ranging from 0.1-100figml-' at four log
increments and the dishes incubated for 4 days at 37°C in an
atmosphere of 5% CO2. Prior to the addition of 20 IL MTT
(5 mgml-'), 150IlI old medium was removed and replaced
with fresh medium. The dishes were then incubated for a
further 4h and the purple formazan crystals produced were
dissolved in DMSO. Optical densities of the resulting solu-
tions were read with an ELISA spectrophotometer at a
wavelength of 550 nm. Each drug concentration was assayed
against each cell line eight times and in four independent
experiments. Cytotoxic effects were expressed as percentage
survival of treated plates compared to control plates and the
initial drug concentration required to inhibit cell survival by
50% (IC50) was obtained from semi-logarithmic plots of cell
survival versus concentration.
In vivo studies
Animals Pure strain NMRI mice, aged 6-8 weeks, from our
inbred colony were used throughout this study. They were
fed with a pellet diet (CRM, Labsure, Croydon, England)
and water ad libitum.
Tumour system The development of several transplantable
adenocarcinomas of the colon in mice from primary tumours
induced by prolonged administration of 1,2-dimethyl-
hydrazine has been described elsewhere (Double et al., 1975).
MAC 13 tumours were transplanted into female mice and
MAC 26 tumours into male mice by sc implantation of
tumour fragments (-1 x 2mm) in the flank. MAC 15A
ascites tumour cells were transplanted into male mice by ip
inoculation of I05- 106 tumour cells in 0.2ml 0.9% saline.
Chemotherapy The differing morphology and growth char-
acteristics of the tumour lines necessitated the use of different
chemotherapy protocols. Animals bearing the more rapidly
growing MAC 13 and MAC 15A tumours were allocated
into groups of 5 and chemotherapy commenced 2 days after
implantation. Anti-tumour responses against MAC 13 were
assessed 17 days later by comparing the tumour weights of
treated and control groups and expressed as percentage
tumour weight inhibition while responses against MAC 15A
were determined by comparison of median survival times
(MST) of treated and control groups as described by Geran
et al. (1972). MAC 26 tumour bearers were allocated into
groups of 10. The administration of cytotoxic drugs did not
commence until these slower growing tumours could be
reliably measured (>4 x 4 mm), approximately 17 days after
transplantation. Anti-tumour effects against MAC 26 were
assessed by twice weekly caliper measurements. Tumour
volumes were calculated from the formula a2 x b/2, where a
is the smaller diameter and b is the larger (Geran et al., 1972)
normalised with respect to the starting volume and semi-
logarithmic graphs of relative tumour volume against time
were plotted. Therapeutic effects were expressed as the re-
growth delay which was obtained by comparing the times
taken by treated and control tumours to reach a tumour
volume ten times that of the starting volume.
Bone marrow toxicity Acute bone marrow toxicity was
assessed using a modified version of the spleen colony form-
ing unit assay of Till and McCulloch (1961). The drugs were
administered by a single ip injection to pairs of male mice
and bone marrow toxicity was assayed 24h later. Marrow
cells were obtained from both femora of each pair of treated
mice and pairs of untreated control mice and suspended in
RPMI 1640 tissue culture medium. Cell suspensions were
diluted so that a 0.2 ml aliquot contained an appropriate
number of cells for each experimental group. Cell inocula of
5.0 x 104-7.5 x 105 were initially obtained from the marrows
of control mice to investigate the relationship between the
number of spleen colonies formed and the number of marrow
cells inoculated. Subsequently, a cell inoculum of 1.0 x
105-2.5 x 105 was prepared from both treated and control
marrows. The marrow cells were then injected iv via the tail
vein into mice which had previously been exposed to irradia-
tion from a Newton Victor Superficial Therapy Unit
(GX x 10) at a dose of 11.7 Gy. Groups of six mice were
used for each experimental point. After 8 days the mice were
killed, the spleens removed and fixed in Bouin's fluid and the
nodules on the spleen surface were counted. The survival
fraction was determined by comparing the number of col-
onies observed with the number of colonies expected for a
given cell inoculum of untreated marrow cells.ANTI-TUMOUR ACTIVITY AND BONE MARROW TOXICITY OF CLOMESONE 443
Pharmacokinetic studies
Sample collection Clomesone was administered to female
non-tumour bearing mice by a single ip injection at a dose of
50 mgkg-'. Blood samples were obtained at time intervals
ranging from 2 min to 2h by cardiac puncture under
diethylether anaesthesia. The samples were placed in
heparinised tubes, centrifuged at 4°C (1000 g for 5 min) and
the plasma stored at - 20°C until analysed. Each time point
was represented by two mice and three independent
experiments were performed.
Sample extraction Siliconised glassware was used through-
out the extraction procedure to minimise drug binding to
vessel walls and all samples and reagents were kept on ice
whenever possible. A 200 gIl aliquot of mouse plasma was
mixed with 50 pl. 2-chloroethyl-p-toluenesulphonate (Sigma
Chemical Company Limited, Poole, UK) as an internal stan-
dard, diluted with 0.9% saline and extracted with 6 ml
diethylether. Following centrifugation (1000 g for 5 min at
4°C), the organic layer was decanted and 1 g anhydrous
sodium sulphate was added to remove any excess water.
After a further centrifugation step to remove the sodium
sulphate, the diethylether layer was evaporated in a stream of
nitrogen in a water bath at 25°C and the dried sample was
reconstituted in 100Il ethyl acetate.
Sample analysis Plasma Clomesone levels were analysed by
gas chromatography. The chromatographic system consisted
of a Shimadzu GC-14A chromatograph fitted with a 63Ni
electron capture detector (Dyson Instruments Limited, Tyne
& Wear, UK) and linked to a Varian 4290 integrator (Varian
Instrument Group, California, USA). The analytical column
was a quartz capillary column (25 m x 0.25 mm id) coated
with 0.2 lim SE-30 (Philips Analytical, Cambridge, UK).
Operating temperatures for injector, column and detector
were 225, 195 and 295°C respectively. High purity CP grade
nitrogen (BOC Limited, London, UK) was used as the car-
rier gas at a flow rate of 1.0 mlmin-' and as the detector
make up gas at a flow rate of 30 mlmin-'. A sample injec-
tion volume of 1 gll was used and the split ratio was set at
1:40. Plasma drug concentrations were determined using an
internal standard method based on peak areas and plotted as
a function of time. Linear regression analysis of the terminal
log-linear phase of the curve was used to determine the 1st
order elimination rate constant (kl) and the terminal half-life
(t1/2) was calculated from the equation:
t1/2= In2/ke,
The area under the plasma concentration versus time curve
(AUC) was calculated from t = 0 to the last measured time
point (tz) using the trapezoidal rule. The remaining area from
tz to t8.o was calculated using the equation Cz/ke, where Cz is
the concentration at tz.
In vitro stability studies
The stability of Clomesone was assayed in complete RPMI
1640 tissue culture medium at 37°C at an initial drug concen-
tration of igml '. Sample aliquots were removed at time
intervals up to 7h and extracted and analysed by gas
chromatography as described for mouse plasma samples. The
1st order rate constant (k) was obtained from a semi-
logarithmic plot of concentration versus time and used to
calculate the drug half-life. In addition this rate constant was
used to construct the drug decay curves for the time course
of the MTT assay of the initial concentrations required to
achieve a 50% cell kill (IC50 values) for each tumour cell line
using the equation:
Ct = Coekt
Concentration-time products (c x t), a measure of the total
drug exposure of the tumour cells in vitro, were then deter-
mined by calculating the areas under the decay curves using
the trapezoidal rule.
Results
Table I shows the in vitro chemosensitivity of the panel of
tumour cell lines to Clomesone. In general, the murine cell
lines were more sensitive than the human cell lines. MAC
15A was the most sensitive with an IC50 value of
10.1 tigml-'. The human leukaemia K562 and a colon cell
line HCLO showed some sensitivity to Clomesone, but it was
relatively inactive against the majority of human cell lines
derived from solid tumours with IC50 values in excess of
100pggml-'.
The in vivo activity of Clomesone against the MAC
tumour lines was compared with that of TCNU and
Chlorozotocin (Tables II-IV). Full dose range data to the
point of toxicity were obtained to assure that maximum
tolerated doses were achieved for each compound and are
presented in Table IV. Activity of Clomesone against each
tumour line was reproduced in a separate experiment as was
the activity of TCNU and Chlorozotocin against MAC 26.
The values obtained for TCNU and Chlorozotocin against
MAC 13 and MAC 15A were similar to those in previously
reported studies (Bibby et al., 1988a; McElhinney et al.,
1989).
Table II shows that Clomesone was active against the
ascitic MAC 15A tumour at doses of 50 mgkg-' and
Table I In vitro chemosensitivity to Clomesone
IC50 igm9l-' cxt
Cell line (mean ± SD; n = 4) (fig h ml-')
MAC 15A 10.1± 1.5 54
MAC 16 33.6± 12.5 177
MAC 26 35a 185
WEHI-3B 28.4± 4.8 150
K562 39.2 ± 14.6 207
HCT-18 > 100 > 528
HRT-18 > 100 > 528
HCLO 27.6 ± 12.0 146
DLD-1 > 100 > 528
HT-29 > 100 > 528
'One experiment only.
Table II Anti-tumour activity against MAC 15A
Dose
Compound (mgkg-') Route T/C%
Clomesone looa ip 133, 163b
50 ip 163
50 iv 125
25 ip 138
25 iv 100
12.5 ip 88
12.5 iv 100
TCNU 30a ip 200
Chlorozotocin 60a ip 288
aMaximum tolerated dose. bTwo independent experiments.
Table III Anti-tumour activity against MAC 13
% Tumour
Dose weight
Compound (mgkg-') Route inhibition
Clomesone looa ip 48.3, 45.0b
50 ip 33.8, 35.lb
50 iv 47.3
25 ip 13.5
25 iv 21.6
12.5 ip 21.6
12.5 iv 45.9
TCNU 30a ip 91.3
Chlorozotocin 60a ip 59.2
'Maximum tolerated dose. bTwo independent experiments.444 A.M. MATTHEW etal.
Table IV Anti-tumour activity against MAC
administration
26 following ip
Tumour
Dose growth
Compound (mg kg-') Survivors delay (days)
Clomesone 200 0/10 Toxic
150 0/10 Toxic
Iooa 10/10 0.8, 0.8b
50 10/10 0.8
25 10/10 0
TCNU 50 0/5 Toxic
30a 10/10 11.6, 12.4b
Chlorozotocin 80 3/9 Toxic
60a 9/9 0, ob
aMaximum tolerated dose. bTwo independent experiments.
100 mgkg`ip. The increases in median survival times were
significant at the 1% level when compared to the control
group using the Mann-Whitney U test. However, at the
maximum tolerated doses the activity of Clomesone was
inferior to that of TCNU and Chlorozotocin. Anti-tumour
activity against the relatively nitrosourea-sensitive solid sc
MAC 13 tumour is presented in Table III. Although the
tumour weight inhibitions achieved by Clomesone at
100mgkg-'ip and 50 mgkg-'ip or iv were significant
(P = 0.05; student's t-test), they were less than that achieved
by TCNU. Clomesone was inactive against the relatively
nitrosourea-resistant solid sc MAC 26 tumour as described in
Table IV. The relative tumour volumes of the group treated
with the maximum tolerated dose of 100 mgkg-'ip were not
significantly different (P>0.1) from those of the control
group when analysed using the student's t-test.
The spleen colony forming unit assay calibration curve is
shown in Figure 2. Linear regression analysis showed a
strong positive correlation (r = 0.997) between the number of
surface spleen colonies and the number of marrow cells
inoculated. Linearity was observed over the range
1.2 x 104-7.4 x I05 cells injected. A cell inoculum below
1.2 x 104 produced no visible surface colonies while a cell
inoculum of 3.4 x 106 resulted in the total repopulation of
the spleen with no discrete colony formation.
Acute bone marrow toxicity following ip drug administra-
tion is described in Table V. The results at the maximum
tolerated dose for each drug represent the survival fractions
obtained in two independent experiments. Clomesone was
less myelosuppressive than TCNU and Chlorozotocin but
still produced a 5-fold reduction in colony forming units at
the maximum tolerated dose of 100 mgkg-'.
The solvent extraction procedure used in the pharmaco-
kinetic studies gave recoveries for six replicate plasma sam-
ples, at a concentration of 1 pgml-', of 98.8% for
Clomesone and 88.9% for the internal standard, 2-chloro-
ethyl-p-toluenesulphonate with an overall intersample varia-
tion for the assay of 9.4%. Adequate separation of Clome-
sone and the internal standard from plasma interferents was
achieved under the assay operating conditions and a typical
chromatogram is presented in Figure 3(a). No underlying
plasma interferent peaks co-eluted with Clomesone as shown
in Figure 3(b). The limit of detection for Clomesone in
plasma was 0.05 Otgml- . A drug calibration curve was con-
structed using least squares linear regression analysis and
linearity was observed in the concentration range
0.05-10figml-' (r = 0.987).
The plasma concentration of Clomesone following ip
administration of 50 mgkg-' as a function of time is shown
in Figure 4. Each point is the mean of duplicate samples and
each curve represents an independent experiment. Peak
plasma levels were reached within 2 min of drug administra-
tion and ranged from 18.1-35.9jigml-' with a mean value of
28.0ggmlh' while the mean terminal half-life was 8.1 min
(range 4.8-10.8 min). The areas under the plasma concentra-
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Figure 2 Spleen colony forming unit assay calibration curve
(points are mean ± SD;n = 6).
Table V Bone marrow toxicity following ip administration
No. colonies
Dose observed Survival
Compound (mgkg-') (mean±SD; n=6) fraction
Clomesone Iooa 4.8 ± 0.75 0.20
iooa 6.5 ± 2.0 0.16
50 11.8±1.17 0.59
25 17.8 ± 0.84 0.80
TCNU 30a 0 0
30a 0 0
10 6.0 ± 0.9 0.20
5 14.0 1.2 0.61
Chlorozotocin 60a 0.33 ± 0.52 0.01
60a 2.25 ± 0.50 0.05
30 21.4± 1.14 0.80
15 24.3 0.96 0.86
aMaximum tolerated dose, two independent experiments.
tion versus time curves ranged from 5.70-8.04laghml-' with
a mean value of 6.77 .ghmlh'. Clomesone degradation in
tissue culture medium exhibited 1st order kinetics with a rate
constant (k) of 0.205 and a t1/2 of 3.38h. The c x t products,
shown in Table I, corresponding to the initial drug concen-
trations required to achieve a 50% cell kill in vitro ranged
from 54->528 ighml-'.
Discussion
Examination of the in vitro activity of Clomesone in a panel
of established murine and human tumour cell lines revealed
that, in general, the human cell lines were insensitive. The
colon adenocarcinoma HCLO and the leukaemia K562 were
the only human cell lines that were sensitive at similar IC50
values. Similarly, in the murine cell lines the concentration
required for a 50% cell kill of the line derived from the
relatively nitrosourea-resistant MAC 26 tumour was of theANTI-TUMOUR ACTIVITY AND BONE MARROW TOXICITY OF CLOMESONE 445
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Figure 3 a, Chromatogram of mouse plasma extract containing
Clomesone and internal standard (1 = Clomesone; 2 = internal
standard). b, Chromatogram of mouse plasma extract containing
internal standard only (1 = position of Clomesone peak;
2 = internal standard).
same order of magnitude as that required by the leukaemia
WEHI-3B. These findings suggested that Clomesone had no
preferential specificity for cell lines derived from solid
tumours.
The lack of selectivity was confirmed by the results of the
in vivo anti-tumour activity and toxicity studies. The activity
of Clomesone in the MAC tumour system in vivo was not
impressive. Moderate activity was exhibited against the
0 10 20 30 40 50 60 70
Time (min)
Figure 4 Plasma concentration of Clomesone following adminis-
tration of 50mgkg lip (points are mean values; n = 2; three
independent experiments).
ascitic MAC 15A. The solid sc MAC 13 did respond to
Clomesone over a broad dose range but the maximum anti-
tumour activity exhibited was not great in this relatively
nitrosourea-sensitive tumour. No significant activity was
demonstrated against the relatively nitrosourea-resistant solid
sc MAC 26 tumour. Thus, the anti-tumour activity of
Clomesone was similar, if slightly inferior, to that of the
non-carbamoylating nitrosourea, Chlorozotocin, and it was
much less effective than the carbamoylating nitrosourea,
TCNU, which remains the most active nitrosourea analogue
in the MAC tumour system to date. Although Clomesone
exhibited less bone marrow toxicity compared to both
TCNU and Chlorozotocin, the reduction in colony forming
units produced at the maximum tolerated dose was still
marked. In addition, the dose of TCNU which produced a
similar level of bone marrow toxicity has been reported to
give a better response than Clomesone against the nitro-
sourea-sensitive MAC 13 tumour (Bibby et al., 1988a).
The development of the selective and sensitive method for
the quantitative determination of Clomesone in mouse
plasma allowed the pharmacokinetic behaviour of the drug
to be characterised with a view to relating the activity-
toxicity pattern to bioavailability. The AUC values for
Clomesone following a single ip injection of 50 mgkg- ,
when considered in conjunction with the in vitro c x t prod-
uct for MAC 26, suggested that the inactivity in vivo was due
to ineffective anti-neoplastic drug concentrations at the
tumour site. A higher drug exposure of the tumour cells
could be achieved in vitro as the drug half-life in tissue
culture medium of 3.38h reported in this study was much
longer than the previously reported t1/2 of Clomesone in
mouse plasma of 0.85h (Chan & Barrientos, 1988). The dose
of 50mgkg-' was chosen as the optimal dose as the higher
maximum tolerated dose of 100mgkg-' resulted in no im-
provement in anti-tumour activity at the expense ofincreased
-- V.Z I
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bone marrow toxicity.
Clomesone was selected for clinical trial on the basis that
although it was only as effective as the chloroethylnit-
rosoureas in some murine tumour models, its chemistry sug-
gested that it would be more toxicologically selective. The
broader pre-clinical evaluation performed in this study could
find no evidence to support this theory. On the contrary, the
findings suggested that the effectiveness of Clomesone, in
common with the chloroethylnitrosoureas, would be limited
by myelosuppression. Whether the results of this study will
be reflected in the clinical setting remains to be seen and the
results of the recently completed Phase I clinical trial are
awaited with great interest.
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